Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring.

Roughley, Matthew; Mena, Carlos; Howard, Robert; Reeves, Suzanne; Bertrand, Julie

Roughley, Matthew; Mena, Carlos; Howard, Robert; Reeves, Suzanne; Bertrand, Julie.

Afiliação

Roughley M; Division of Psychiatry, University College London, London, UK.
Mena C; Division of Psychiatry, University College London, London, UK.
Howard R; Institute of Cognitive Neuroscience, University College London, London, WC1N 3AZ, UK.
Reeves S; Division of Psychiatry, University College London, London, UK.
Bertrand J; Division of Psychiatry, University College London, London, UK.

Br J Clin Pharmacol ; 89(7): 2316-2321, 2023 07.

Article em En | MEDLINE | ID: mdl-36791792

Assuntos

Doença de Alzheimer; Antipsicóticos; Humanos; Risperidona/efeitos adversos; Antipsicóticos/uso terapêutico; Doença de Alzheimer/tratamento farmacológico; Monitoramento de Medicamentos; Teorema de Bayes

Palavras-chave

Alzheimer's disease; Bayesian; pharmacokinetics; poor metabolizer; risperidone

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antipsicóticos / Doença de Alzheimer Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google